Syros Pharmaceuticals

Biotech

Syros buys Tyme, securing $190M to extend cash runway into 2025

By merging with the floundering Tyme and tapping investors including Flagship, Syros has extended its cash runway out into 2025.
Nick Paul Taylor Jul 5, 2022 9:40am

Syros targets KRAS-mutant cancer with CDK7 inhibitor

Sep 20, 2021 11:30am

Syros links SY-1425 combo to 50%-plus AML complete response rate

Oct 25, 2019 10:15am

Syros cans solid tumor drug after seeing early clinical data

Oct 17, 2019 8:48am

A new approach to resistant prostate cancer

Aug 29, 2019 9:00am

Syros tanks on single-digit response rate in AML, MDS trial 

Dec 11, 2017 8:58am